Risk of VTE in the UKB according to genotype after adjustment for common risk factors
| . | Carriers/total (%) . | Carriers/noncarriers . | OR (95% CI) . | P value . | |
|---|---|---|---|---|---|
| Cases . | Controls . | ||||
| Genotype | |||||
| PTGM heterozygous | 8 854/425 690 (2.0) | 584/16 589 | 8 270/16 589 | 1.72 (1.58-1.88) | <1 × 10−16 |
| PTGM homozygous | 45/416 881 (0.01) | 3/16 589 | 42/16 589 | 2.18 (0.59-5.76) | .21 |
| FVL heterozygous | 18 786/435 622 (4.3) | 1 541/16 589 | 17 245/16 589 | 2.18 (2.06-2.31) | <1 × 10−16 |
| FVL homozygous | 210/417 046 (0.05) | 43/16 589 | 167/16 589 | 7.14 (5.01-9.97) | <1 × 10−16 |
| DH | 413/417 249 (0.1) | 64/16 589 | 349/16 589 | 4.53 (3.42-5.90) | <1 × 10−16 |
| Other factors | |||||
| Male sex | 191 246/417 249 (46) | 7 589/9 064 | 183 657/216 939 | 0.95 (0.91-0.97) | 6.2 × 10−5 |
| Age∗ | N/A | 60.1 ± 7.2 | 56.9 ± 8.1 | 1.05 (1.05-1.06) | <1 × 10−16 |
| BMI† | N/A | 29.2 ± 5.6 | 27.3 ± 4.7 | 1.06 (1.06-1.07) | <1 × 10−16 |
| Blood group O | 181 172/417 249 (43) | 5 992/10 661 | 175 180/225 416 | 0.72 (0.69-0.74) | <1 × 10−16 |
| Smoking | 188 934/417 249 (45) | 8 528/8 125 | 180 406/220 190 | 1.15 (1.11-1.18) | <1 × 10−16 |
| Platelet count‡ | N/A | 252.8 ± 63.8 | 253.1 ± 59.7 | 1.00 (1.00-1.00) | .69 |
| CRP§ | N/A | 3.5 ± 5.6 | 2.5 ± 4.3 | 1.02 (1.01-1.02) | <1 × 10−16 |
| . | Carriers/total (%) . | Carriers/noncarriers . | OR (95% CI) . | P value . | |
|---|---|---|---|---|---|
| Cases . | Controls . | ||||
| Genotype | |||||
| PTGM heterozygous | 8 854/425 690 (2.0) | 584/16 589 | 8 270/16 589 | 1.72 (1.58-1.88) | <1 × 10−16 |
| PTGM homozygous | 45/416 881 (0.01) | 3/16 589 | 42/16 589 | 2.18 (0.59-5.76) | .21 |
| FVL heterozygous | 18 786/435 622 (4.3) | 1 541/16 589 | 17 245/16 589 | 2.18 (2.06-2.31) | <1 × 10−16 |
| FVL homozygous | 210/417 046 (0.05) | 43/16 589 | 167/16 589 | 7.14 (5.01-9.97) | <1 × 10−16 |
| DH | 413/417 249 (0.1) | 64/16 589 | 349/16 589 | 4.53 (3.42-5.90) | <1 × 10−16 |
| Other factors | |||||
| Male sex | 191 246/417 249 (46) | 7 589/9 064 | 183 657/216 939 | 0.95 (0.91-0.97) | 6.2 × 10−5 |
| Age∗ | N/A | 60.1 ± 7.2 | 56.9 ± 8.1 | 1.05 (1.05-1.06) | <1 × 10−16 |
| BMI† | N/A | 29.2 ± 5.6 | 27.3 ± 4.7 | 1.06 (1.06-1.07) | <1 × 10−16 |
| Blood group O | 181 172/417 249 (43) | 5 992/10 661 | 175 180/225 416 | 0.72 (0.69-0.74) | <1 × 10−16 |
| Smoking | 188 934/417 249 (45) | 8 528/8 125 | 180 406/220 190 | 1.15 (1.11-1.18) | <1 × 10−16 |
| Platelet count‡ | N/A | 252.8 ± 63.8 | 253.1 ± 59.7 | 1.00 (1.00-1.00) | .69 |
| CRP§ | N/A | 3.5 ± 5.6 | 2.5 ± 4.3 | 1.02 (1.01-1.02) | <1 × 10−16 |
Data are represented for 484 206 individuals.
An extended Firth logistic regression model was generated using the clinical annotation and phenotyping data. The third and fourth columns display the number of VTE cases and controls stratified by genotype and other covariates, respectively. For each comparison, noncarriers of both FVL and PTGM were used as the reference value (OR = 1.0).
N/A, not applicable.
Per 1-year increase.
Per 1 kg/m2 increase.
Per 1000/μL increase.
Per 1 mg/dL increase.